Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Share-based Compensation (2016 - 2025)

Mimedx's Share-based Compensation history spans 15 years, with the latest figure at $2.5 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 47.52% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $16.4 million, down 3.17%, while the annual FY2025 figure was $16.4 million, 3.17% down from the prior year.
  • Share-based Compensation for Q4 2025 was $2.5 million at Mimedx, down from $4.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.9 million in Q3 2025 and bottomed at $530000.0 in Q4 2022.
  • The 5-year median for Share-based Compensation is $4.1 million (2021), against an average of $3.8 million.
  • The largest annual shift saw Share-based Compensation plummeted 82.57% in 2022 before it skyrocketed 727.55% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $3.0 million in 2021, then tumbled by 82.57% to $530000.0 in 2022, then surged by 727.55% to $4.4 million in 2023, then rose by 7.0% to $4.7 million in 2024, then plummeted by 47.52% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Share-based Compensation are $2.5 million (Q4 2025), $4.9 million (Q3 2025), and $4.8 million (Q2 2025).